For Healthcare Professionals
Rucaparib is an investigational, orally available, small-molecule poly (ADP-ribose) polymerase (PARP) inhibitor that is a potent inhibitor of PARP1 and PARP2. Clovis intends to develop rucaparib for the treatment of cancers predisposed to PARP inhibitor sensitivity, with an initial focus on ovarian cancer with BRCA mutations or other DNA repair deficiencies. Rucaparib has been granted Breakthrough Therapy Designation from the FDA for the monotherapy treatment of patients with advanced ovarian cancer who have BRCA-mutant tumors (inclusive of both germline and somatic BRCA mutations). Rucaparib is an investigational drug and has not been approved by any Health Authority, therefore conclusions about safety or efficacy cannot be made. As a result, it is currently only available through clinical trials.